Cell Therapeutics, Inc.

Kaneka Corporation

Washington Research Foundation

David J Porubek

Paul Woodson

Jack W Singer

James A Bianco

J Peter Klein

Gail E Underiner

Anil M Kumar

Lynn Massman Rose

Alan B Montgomery

Charles R Bredl

Alistair J Leigh

Glenn C Rice

John E Tulinsky

John Michnick

Stephen J Klaus

Elisa Eiseman

Patrick J Bednarski

Sidney D Nelson

A method for treatment of bacterial infections with rifalazil administered once-weekly, or twice-weekly. A method for treatment of tuberculosis caused by, infections caused bycomplex, infections caused byand infections caused byby administering to a patient suffering from the bacterial infection 1-100 mg of rifalazil once or twice a week. In this dose regimen, the treatment is fast, efficacious and eliminates undesirable secondary symptoms observed with daily doses of 1-50 mg of rifalazil.

Method for treatment of bacterial infections with once or twice-weekly administered rifalazil

Disclosed are compounds having selective hydrolytic potential. The disclosed compounds are useful as compounds having selective stability and are capable of undergoing programmed hydrolysis in biologic systems.

Compounds having selective hydrolytic potentials

Disclosed are compounds having selective hydrolytic potential. The disclosed compounds are useful as compounds having selective stability and are capable of undergoing programmed hydrolysis in biologic systems. The disclosed compounds have a structure of formula I:

Hydroxyl-containing compounds

A method for treatment of bacterial infections with rifalazil administered once-weekly or twice-weekly. A method for treatment of tuberculosis caused by , infections caused by complex, infections caused by and infections caused by by administering to a patient suffering from the bacterial infection 1-100 mg of rifalazil once or twice a week. In this dose regimen, the treatment is fast, efficacious and eliminates undesirable secondary symptoms observed with daily doses of 1-50 mg of rifalazil.

A method for treatment of bacterial infections with rifalazil administered once-weekly or twice-weekly. A method for treatment of tuberculosis caused by,, infections caused by,complex, infections caused by,and infections caused by,by administering to a patient suffering from the bacterial infection 1-100 mg of rifalazil once or twice a week. In this dose regimen, the treatment is fast, efficacious and eliminates undesirable secondary symptoms observed with daily doses of 1-50 mg of rifalazil.

Disclosed are therapeutic compounds having the formula:

Hydroxyl-containing bicyclic compounds

There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.

Enantiomerically pure hydroxylated xanthine compounds

Therapeutic compounds containing a monocyclic five- to six- membered

Enatiomerically pure hydroxylated xanthine compounds

Hydroxyl-containing xanthine compounds

Enantiomerically pure hydroxylated xanthine compounds to treat

Treatment of diseases using enantiomerically pure hydroxylated xanthine

There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in treating inflammatory disease.

Enatiomerically pure hydroxylated xanthine compounds to treat

Growing community of inventors

Seattle, WA, United States of America

David J Porubek